{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:16:37Z","timestamp":1788261397776,"version":"build-2803163510"},"reference-count":132,"publisher":"Informa UK Limited","issue":"9","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100014481","name":"Kite Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014481","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2026,9,2]]},"DOI":"10.1080\/17474086.2026.2688385","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T23:49:05Z","timestamp":1781135345000},"page":"1091-1106","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic factors for patients with relapsed or refractory multiple myeloma who are initiating a fourth or later line car T-cell or bispecific antibody therapy: a systematic literature review and meta-analysis"],"prefix":"10.1080","volume":"19","author":[{"given":"Krina","family":"Patel","sequence":"first","affiliation":[{"name":"University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, Kite","place":["Santa Monica, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ting","sequence":"additional","affiliation":[{"name":"Arcellx, Inc","place":["Redwood City, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine","place":["Stanford, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Zoratti","sequence":"additional","affiliation":[{"name":"RainCity Analytics","place":["Vancouver, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wennersbusch","sequence":"additional","affiliation":[{"name":"RainCity Analytics","place":["Vancouver, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0322-5398","authenticated-orcid":false,"given":"Steve","family":"Kanters","sequence":"additional","affiliation":[{"name":"RainCity Analytics","place":["Vancouver, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Kostic","sequence":"additional","affiliation":[{"name":"Arcellx, Inc","place":["Redwood City, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Itani","sequence":"additional","affiliation":[{"name":"Real World Evidence Generation, Kite, A Gilead Company","place":["Santa Monica, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center & Research Institute","place":["Tampa, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.183475"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2128"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08280-y"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.098608"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.830922"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000045"},{"key":"e_1_3_5_9_1","article-title":"Systematic literature review and meta-analysis of clinical interventions for the treatment of relapsed\/refractory multiple myeloma patients with three or more prior lines of therapy (4L+)","author":"Zoratti Mk S","year":"2023","unstructured":"Zoratti Mk S, Limbrick-Oldfield E, Zannat NE, et al. Systematic literature review and meta-analysis of clinical interventions for the treatment of relapsed\/refractory multiple myeloma patients with three or more prior lines of therapy (4L+). PROSPERO. 2023. https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42023446880","journal-title":"PROSPERO"},{"key":"e_1_3_5_10_1","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). General Methods (Allgemeine Methoden) Version 6.1. In: IQWiG editor. 2022."},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"e_1_3_5_13_1","volume-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells GA","year":"2000","unstructured":"Wells GA, Shea B, O\u2019Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Oxford; 2000 Feb 9."},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.3102\/10769986030003261"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1482"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.6.676"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.010"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2019-300117"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-206867"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02589-w"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-162440"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-203609"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01910-4"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134322"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-198763"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01008"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-211739"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-188655"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159707"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199374"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158563"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015526"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022823"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-206413"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)00951-0"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01068-w"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.016"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19302"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180458"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-203409"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-182628"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19505"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-164884"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00886-8"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011225"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02129-y"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01924-4"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009220"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01928-1"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-210350"},{"issue":"3","key":"e_1_3_5_53_1","first-page":"6","article-title":"Idecabtagene vicleucel (ide-cel, bb2121) in relapsed and refractory multiple myeloma (RRMM): analyses of high-risk subgroups in the KarMMa study","volume":"45","author":"Goldschmidt Hr N","year":"2022","unstructured":"Goldschmidt Hr N, Siegel D, Jagannath S, et al. Idecabtagene vicleucel (ide-cel, bb2121) in relapsed and refractory multiple myeloma (RRMM): analyses of high-risk subgroups in the KarMMa study. Oncol Res Treat. 2022;45(Suppl. 3):6\u2013285.","journal-title":"Oncol Res Treat"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181304"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204232"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)02170-0"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180283"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012724"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01931-1"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-197929"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8012"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01365"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-164828"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283888"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-CT001"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146069"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(21)02101-7"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.05.025"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.05.006"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970424.05174.3c"},{"issue":"2","key":"e_1_3_5_71_1","first-page":"S212","article-title":"Linvoseltamab in patients with relapsed\/refractory multiple myeloma in the LINKER-MM1 study: depth and durability of response at 14-month median follow-up","volume":"8","author":"Lentzsch S","year":"2024","unstructured":"Lentzsch S, Lee H, Suvannasankha A. Linvoseltamab in patients with relapsed\/refractory multiple myeloma in the LINKER-MM1 study: depth and durability of response at 14-month median follow-up. Hemasphere. 2024;8(Suppl 2):S212.","journal-title":"Hemasphere"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008320"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(23)01466-0"},{"issue":"1","key":"e_1_3_5_75_1","first-page":"1","article-title":"Correlation of tumor BCMA expression with response and acquired resistance to idecabtagene vicleucel in the KarMMa study in relapsed and refractory multiple myeloma","volume":"4","author":"Martin Nt E","year":"2020","unstructured":"Martin Nt E, Dell\u2019aringa J, Paiva B, et al. Correlation of tumor BCMA expression with response and acquired resistance to idecabtagene vicleucel in the KarMMa study in relapsed and refractory multiple myeloma. Hemasphere. 2020;4(S1):1\u20131168.","journal-title":"Hemasphere"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200675"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00690"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200877"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-023-00989-z"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187565"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204228"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01003-z"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967696.13096.54"},{"issue":"2","key":"e_1_3_5_84_1","first-page":"e70012","article-title":"Long-term survival after Elranatamab monotherapy in patients with relapsed or refractory multiple myeloma (RRMM): MagnetisMM-3","volume":"8","author":"Mohty Mi S","year":"2024","unstructured":"Mohty Mi S, Bahlis NJ, Sullivan S, et al. Long-term survival after Elranatamab monotherapy in patients with relapsed or refractory multiple myeloma (RRMM): MagnetisMM-3. Hemasphere. 2024;8(S2):e70012.","journal-title":"Hemasphere"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-206900"},{"key":"e_1_3_5_88_1","first-page":"e566","article-title":"Idecabtagene vicleucel (ide-cel, bb2121), a bcma-directed car t cell therapy, in patients with relapsed and refractory multiple myeloma: updated karmma results","volume":"5","author":"Oriol As-M J","year":"2021","unstructured":"Oriol As-M J, Kansagra A, Madduri D. Idecabtagene vicleucel (ide-cel, bb2121), a bcma-directed car t cell therapy, in patients with relapsed and refractory multiple myeloma: updated karmma results. Hemasphere. 2021;5:e566.","journal-title":"Hemasphere"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-206357"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-205989"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158478"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-210078"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166494"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01974-8"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02154-5"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-203735"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(23)01415-5"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000829648.85784.e2"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970368.33859.48"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10824-3"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199733"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148375"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-211018"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-210976"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.896"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7567"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01852-4"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025945"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-6367(23)00111-2"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283940"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166058"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204158"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-183085"},{"issue":"2","key":"e_1_3_5_114_1","first-page":"e70012","article-title":"Real-world schedule De-escalation of Teclistamab in patients with relapsed\/refractory multiple myeloma","volume":"8","author":"Tan Cd A","year":"2024","unstructured":"Tan Cd A, Maclachlan K, Hullcrantz M, et al. Real-world schedule De-escalation of Teclistamab in patients with relapsed\/refractory multiple myeloma. Hemasphere. 2024;8(S2):e70012.","journal-title":"Hemasphere"},{"key":"e_1_3_5_115_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-210518"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970532.16622.f0"},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023616"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000967676.59550.94"},{"key":"e_1_3_5_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01667-7"},{"key":"e_1_3_5_120_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7508"},{"key":"e_1_3_5_121_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01555-4"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003655"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2005.01.012"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00283-0"},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.03.013"},{"key":"e_1_3_5_126_1","doi-asserted-by":"publisher","DOI":"10.17305\/bb.2025.12129"},{"key":"e_1_3_5_127_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02677-5"},{"key":"e_1_3_5_128_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13010264"},{"key":"e_1_3_5_129_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4812637"},{"key":"e_1_3_5_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.07.003"},{"key":"e_1_3_5_131_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-025-00338-1"},{"key":"e_1_3_5_132_1","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000006270"},{"key":"e_1_3_5_133_1","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11120875"},{"key":"e_1_3_5_134_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000005.pub4"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2026.2688385","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/17474086.2026.2688385","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2026.2688385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:33:17Z","timestamp":1788258797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2026.2688385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":132,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,2]]}},"alternative-id":["10.1080\/17474086.2026.2688385"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2026.2688385","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-05-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}